Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceutical Chemicals

Seqens adds pharmaceutical chemical capacity in France

by Michael McCoy
September 4, 2020 | A version of this story appeared in Volume 98, Issue 34

 

A photo of French president Emmanuel Macron touring a pharmaceutical chemical plant.
Credit: Seqens
French president Emmanuel Macron (center) tours Seqens's new facility.

At an event attended by French president Emmanuel Macron, Seqens inaugurated a facility in Villeneuve-la-Garenne, France, that produces highly potent active pharmaceutical ingredients. Built at a cost of about $35 million, the plant will make the contraceptive hormone estetrol for Mithra, a Belgian biotech firm. Mithra expects products containing estetrol to win approval next year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.